EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
东部肿瘤合作组 - 威斯康星州研究
基本信息
- 批准号:7426841
- 负责人:
- 金额:$ 61.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1978
- 资助国家:美国
- 起止时间:1978-06-01 至 2010-04-30
- 项目状态:已结题
- 来源:
- 关键词:AccountabilityAcute Myelocytic LeukemiaAddressAdenocarcinomaAdenovirus p53AdherenceAdjuvantAdjuvant ChemotherapyAdjuvant TherapyAdverse eventAesculus hippocastanumAffectAfrican AmericanAlaska NativeAmbulatory Care FacilitiesAmericanAmerican Indian and Alaska NativeAmerican IndiansAmerican Society of Clinical OncologyAnthracycline AntibioticsAnthracyclinesAntineoplastic AgentsApplications GrantsAppointmentAreaArsenic trioxide/Ascorbic acidArt TherapyArteriesAsiansAssociation of Community Cancer CentersAwardAxillary lymph node groupB-LymphocytesBedsBehaviorBerlinBibliographyBilateralBiliaryBiological Response Modifier TherapyBlast PhaseBloodBlood VesselsBlood specimenBone DensityBone Marrow TransplantationBrainBrain NeoplasmsBreastBronchoalveolar LavageCalendarCancer BurdenCancer CenterCancer Center Support GrantCancer ControlCancer ModelCancer PatientCancer SurvivorCancer Therapy Evaluation ProgramCandidate Disease GeneCaracemideCarboplatinCarboplatin/PaclitaxelCarboplatin/Paclitaxel/ThalidomideCarboxyamidotriazoleCarcinomaCaringCarmustineCategoriesCellsCenter Core GrantsCervix UteriCessation of lifeChemopreventionChemotherapy-Oncologic ProcedureChestChronicChronic Lymphocytic LeukemiaCisplatinCisplatin/PaclitaxelCitiesCladribineClinicClinicalClinical NursingClinical PharmacologyClinical ResearchClinical Research AssociateClinical TreatmentClinical TrialsClinics and HospitalsCoffeeCollaborationsColonColon CarcinomaColorectalColorectal CancerCommitCommittee MembersCommunicationCommunitiesCommunity Clinical Oncology ProgramCommunity Health CentersCompanionsComplexComprehensive Cancer CenterCountCountryCountyCritiquesCyclophosphamideCyclophosphamide/Doxorubicin/Interferon Alfa/Prednisone/VincristineDL-alpha-DifluoromethylornithineDacarbazineDailyDataData CollectionData QualityDatabasesDepthDevelopmentDevelopmental Therapeutics ProgramDiagnosticDiffuseDiffuse Large-Cell LymphomaDiscipline of NursingDiseaseDisease remissionDocetaxel/GemcitabineDoctor of PharmacyDoctor of PhilosophyDocumentationDoseDouble-Blind MethodDoxorubicinDropsEastern Cooperative Oncology GroupEchinomycinEconomicsEducationEducational CurriculumEducational workshopElderlyEnrollmentEnsureEpidermal Growth Factor ReceptorEpithelialEsophagealEsophageal AdenocarcinomaEsophageal Squamous Cell CarcinomaEsophagectomyEsophagogastric JunctionEsophagusEstramustineEthnic OriginEthnicity not ReportedEtoposideEvaluationEvaluation StudiesExcisionExpressed Sequence TagsExtensive StageFacultyFamilyFatigueFellowshipFellowship ProgramFemaleFinancial compensationFloxuridineFludarabine/RituximabFluorouracilFluorouracil/LevamisoleFlutamideFollicular LymphomaFosteringFoundationsFoxesFundingFutureGefitinibGenderGene Therapy AgentGenesGenetic VariationGenetsGenotypeGenus ColaGerm cell tumorGlioblastomaGliomaGoalsGrantGranulocyte-Macrophage Colony-Stimulating FactorGray unit of radiation doseGroup MeetingsGroup StructureGrowthGynecologicHeadHead and Neck CancerHead and neck structureHealthHealth Insurance Portability and Accountability ActHealth behaviorHealth care facilityHealth systemHeart DiseasesHematologyHematopathologyHepaticHispanicsHistopathologic GradeHormonesHospital safetyHospitalsHourHousingHumanHypermethylationIllinoisImageImmunotherapyIncidenceIncidence StudyIndividualIndolentIndustryInformation DisseminationInfusion proceduresInpatientsInstitutionInterferon Alfa-2aInterferon Alfa-2bInterferon-alphaInterferon-betaInterferonsInterleukin-1Interleukin-2Internal MedicineInternetIntra-abdominalInvestmentsIowaIrrigationIslet CellIslets of LangerhansIsotretinoinJointsJordanJournalsKidneyKidney FailureLaboratoriesLaboratory ResearchLarge Intestine CarcinomaLeadLeadershipLearningLeftLengthLeucovorinLinear Accelerator Radiotherapy SystemsLocationLomustineLungLung diseasesLymph node excisionLymphedemaLymphomaMGMT geneMaintenanceMaintenance TherapyMalignant Epithelial CellMalignant NeoplasmsMalignant lymphoid neoplasmMalignant neoplasm of esophagusMalignant neoplasm of large intestineMalignant neoplasm of lungMalignant neoplasm of ovaryMalignant neoplasm of pancreasMalignant neoplasm of prostateMantle Cell LymphomaManuscriptsMapsMeasuresMedicalMedical OncologistMedical OncologyMedical centerMedicineMelphalanMenogarilMentorsMeta-AnalysisMetastatic MelanomaMetastatic Neoplasm to the LiverMetastatic Prostate CancerMethotrexateMethylphenidateMichiganMinorityMinority GroupsMitosisModalityMonitorMorphologyMucositisMultiple MyelomaMurine Monoclonal Antibody 2B8MutationMyelogenousN phosphonoacetyl L aspartateN(delta)-acetylornithine, -isomerN-dodecanoylglutamic acid, -isomer, sodium saltN-methylformamideNCI Center for Cancer ResearchNCI-Designated Cancer CenterNamesNational Surgical Adjuvant Breast and Bowel ProjectNative Hawaiian or Other Pacific IslanderNeckNegative Axillary Lymph NodeNeoplasm MetastasisNew AgentsNewly DiagnosedNon-Hodgkin&aposs LymphomaNon-MeasurableNon-Small-Cell Lung CarcinomaNone or Not ApplicableNot Hispanic or LatinoNotificationNumbersNursesNursing ResearchOncologistOncology GroupOntologyOperative Surgical ProceduresOralOrchiectomyOutcomeOutpatientsOvarianOvaryPaclitaxelPainPalliative CarePalliative MedicinePalliative SurgeryPalmar-plantar erythrodysesthesia syndromePancreasPancreatic carcinomaPaperParkinson DiseaseParticipantPathologicPathologyPathology, OtherPatient Care TeamPatientsPelvisPerformancePersonal SatisfactionPharmaceutical PreparationsPharmacologic SubstancePharmacologyPharmacy facilityPhasePhase I Clinical TrialsPhase II Clinical TrialsPhase III Clinical TrialsPhysiciansPilot ProjectsPlanet MarsPlayPoliciesPolicy ResearchPopulationPositioning AttributePositive Lymph NodePostmenopausePostoperative PeriodPoxviridaePredispositionPreparationPreventionPrevention ResearchPrincipal InvestigatorProblem SolvingProcarbazineProceduresProcessProductivityPrognostic FactorProgram DevelopmentProspective StudiesProstateProstate Cancer Prevention TrialProstate carcinomaProstatic Intraepithelial NeoplasiasProtocols documentationPublished CommentPublishingPurposePycnogenolQuality of lifeQuality-of-Life AssessmentRaceRadiationRadiation OncologyRadiation Therapy Oncology GroupRadiation therapyRadical ProstatectomyRadiology SpecialtyRadiosurgeryRadiumRandomizedRandomized Controlled Clinical TrialsRangeRateRecording of previous eventsRecurrenceRefractoryRegulationRelapseRenal Cell CarcinomaReportingResearchResearch ActivityResearch Ethics CommitteesResearch InfrastructureResearch PersonnelResearch SupportResectedResidual stateResistanceResourcesRetirementRetrievalReview CommitteeReview LiteratureRiskRisk FactorsRobin birdRoleRutaS PhaseSDZ-PSC-833SECTM1 geneSafetySalvage TherapySamplingScheduleScienceScientistScreening procedureSeedsSeleniumSemustineServicesSiblingsSideSignal TransductionSiteSite VisitSocial Security NumberSocietiesSouthwest Oncology GroupSpecific qualifier valueStagingStandards of Weights and MeasuresStomachStomach CarcinomaStrategic PlanningStratificationStreptozocinStructureSulindac SulfoneSupratentorialSurgeonSuspension substanceSuspensionsSymptomsSystemTP53 geneTelephoneTestingTextThalidomideTherapeuticTherapeutic StudiesTherapeutics CommitteeTherapy Clinical TrialsThoracic OncologyTimeTitleTodayTopotecanToxic effectTrainingTraining ProgramsTransitional Cell CarcinomaTranslatingTransplantationTravelTreatment ProtocolsTretinoinTrimetrexateTumor BurdenTumor DebulkingUnited States Food and Drug AdministrationUnited States National Institutes of HealthUniversitiesUniversity HospitalsUniversity of Wisconsin Comprehensive Cancer CenterUpdateUpper armUrologyUrotheliumVA-2VaccinationVaccinesVeteransVincristineVinorelbineVisitWagesWest VirginiaWisconsinWolvesWomanWood materialWorkY 90 Ibritumomab TiuxetanZoledronateabstractingalpha-difluoromethyl-DOPA, -isomeralpha-methylornithine dihydrochloride, -isomeranticancer researchauthoritybasecancer carecancer cellcancer research center directorcancer therapycancer typecapecitabinecase findingcelecoxibchemotherapycisplatin/etoposide protocolcitrinclinically relevantcollegecomputerizedconceptcostcyclophosphamide/doxorubicin/lomustine protocoldata managementdaydesigndocetaxeldriving forcedrug developmentexperiencefallsflufollow-upgastrointestinalgemcitabinegene therapyhomoharringtoninehormone therapyhuman prostaglandin D2 receptorhuman subjectiliumimprovedinnovationinstructorinterdisciplinary approachinterestiodonitrotetrazoliumirradiationleukemialung Carcinomalung small cell carcinomamalemalignant breast neoplasmmedical schoolsmelanomamembermenmultidisciplinaryneuropsychiatrynovelnovel strategiesolder patientoligodendrogliomaoncologyoutreach programpatient safetyperformance status 2perilla alcoholpilot trialpiritreximposterspreferenceprobationprofessorprognosticprogramsprospectiveprotocol developmentquality assurancerepositoryresearch studyresponserituximabsexskillssuccesssymposiumsymptom managementtherapy developmenttooltraffickingtrial comparingtumorurinaryurologic
项目摘要
DESCRIPTION (provided by applicant): This application seeks support for the activities of the Eastern Cooperative Oncology Group (ECOG) at the University of Wisconsin Comprehensive Cancer Center (UWCCC) and affiliated institutions. The clinical programs of the UWCCC are designed to improve both the treatment and care of cancer patients as well as to reduce the burden of the cancer problem in general. Our long association with the Eastern Cooperative Oncology Group (ECOG) has been beneficial in enhancing these goals.
UWCCC Investigators have a history of strong commitment to ECOG accrual as well as administrative and scientific leadership. UWCCC clinics are organized along disease specific lines with efforts to enhance the multidisciplinary approaches needed for today's optimal cancer care and clinical research. During the last grant cycle this approach has been strengthened with recruitment in Medical Oncology and Surgery, new clinic space and enhancement of computerized research database facilities. All of this has improved our ECOG effort as manifested by consistent high accrual and group leadership activities. UW investigators chair the GU and Thoracic committees and co-chair the Pharmacology committee. UW investigators will lead chemoprevention efforts in ECOG.
Institutional evaluations consistently rank the UW ECOG program at or near the top in categories of accrual, administrative and scientific leadership. UW ECOG affiliates continue to contribute with significant accrual and high quality data management and rank among the best in ECOG. ECOG studies and a clinical trials approach in cancer care are essential for continued high quality in the cancer programs at UW and throughout the region. ECOG studies serve as a core curriculum for trainees in Hematology and Medical and Radiation Oncology and as a basis for clinical strategies. The ECOG program remains an important component of the UWCCC cancer research effort and UWCCC contributions to ECOG remain equally important to the Group.
描述(由申请人提供):本申请为威斯康星大学综合癌症中心(UWCCC)和附属机构的东部合作肿瘤学小组(ECOG)的活动寻求支持。 UWCCC的临床计划旨在改善癌症患者的治疗和护理,并总体上减轻癌症问题的负担。 我们与东部合作肿瘤学小组(ECOG)的长期关联对增强这些目标是有益的。
UWCCC的调查人员有对ECOG应计,行政和科学领导的坚定承诺的历史。 UWCCC诊所沿疾病特定线进行组织,并努力增强当今最佳癌症护理和临床研究所需的多学科方法。 在上一个赠款周期中,随着医学肿瘤学和手术,新的诊所空间以及计算机研究数据库设施的增强,这种方法得到了加强。 所有这些都改善了我们的ECOG努力,这表现为一贯的高额计费和团体领导活动。 UW研究人员主席GU和胸部委员会和联合主席药理学委员会。 大学研究人员将领导ECOG中的化学预订工作。
机构评估始终在应计,行政和科学领导类别的类别中或顶部将UW ECOG计划排名。 UW ECOG分支机构继续以重要的应计和高质量数据管理贡献,并在ECOG中占据最佳状态。 ECOG研究和癌症护理中的临床试验方法对于UW和整个地区的癌症计划中的持续高质量至关重要。 ECOG研究是血液学,医学和放射肿瘤学学员的核心课程,也是临床策略的基础。 ECOG计划仍然是UWCCC癌症研究工作的重要组成部分,UWCCC对ECOG的贡献对小组仍然同样重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brad Kahl其他文献
Brad Kahl的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brad Kahl', 18)}}的其他基金
Phase I Study of Rituximab with L2-7001 (Aldesleukin) for Non-Hodgkin's Lymphoma
利妥昔单抗联合 L2-7001(Aldesleukin)治疗非霍奇金淋巴瘤的 I 期研究
- 批准号:
7043907 - 财政年份:2003
- 资助金额:
$ 61.06万 - 项目类别:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
东部肿瘤合作组 - 威斯康星州研究
- 批准号:
7661563 - 财政年份:1978
- 资助金额:
$ 61.06万 - 项目类别:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
东部肿瘤合作组 - 威斯康星州研究
- 批准号:
8284229 - 财政年份:1978
- 资助金额:
$ 61.06万 - 项目类别:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
东部肿瘤合作组 - 威斯康星州研究
- 批准号:
8465828 - 财政年份:1978
- 资助金额:
$ 61.06万 - 项目类别:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
东部肿瘤合作组 - 威斯康星州研究
- 批准号:
8079081 - 财政年份:1978
- 资助金额:
$ 61.06万 - 项目类别:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
东部肿瘤合作组 - 威斯康星州研究
- 批准号:
7869601 - 财政年份:1978
- 资助金额:
$ 61.06万 - 项目类别:
相似海外基金
Specialized Program Of Research Excellence (SPORE) in Leukemia.
白血病专业卓越研究计划 (SPORE)。
- 批准号:
10912197 - 财政年份:2013
- 资助金额:
$ 61.06万 - 项目类别:
Eastern Cooperative Oncology Group Chair's Office
东部肿瘤合作组主席办公室
- 批准号:
7262496 - 财政年份:1999
- 资助金额:
$ 61.06万 - 项目类别:
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
东部肿瘤合作组 - 威斯康星州研究
- 批准号:
7257228 - 财政年份:1978
- 资助金额:
$ 61.06万 - 项目类别: